Newly Diagnosed Multiple Myeloma Clinical Trials — 2026 NDMM Pipeline

Active Phase 2 and Phase 3 trials — newly diagnosed multiple myeloma (March 2026)

The table below reflects recruiting and active trials registered on ClinicalTrials.gov targeting newly diagnosed multiple myeloma as of March 2026. DataLookout monitors for new registrations and status changes daily.

Sources: ClinicalTrials.gov. DataLookout monitors for new registrations and status updates daily. Table reflects recruiting and active trials as of March 2026.

The transformation of NDMM therapy: from VRd to Dara-VRd quadruplets

Multiple myeloma is the second most common hematologic malignancy, with approximately 35,000 new diagnoses per year in the United States. It remains incurable in the vast majority of patients, with current treatment goals centered on achieving deep, durable responses that translate into extended progression-free and overall survival.

The NDMM treatment landscape has undergone a step-change over the past decade. VRd (bortezomib + lenalidomide + dexamethasone) was the previous standard of care, yielding median PFS of approximately 40 months in transplant-eligible patients. The addition of daratumumab — a CD38-targeting IgG1 monoclonal antibody — to VRd in the PERSEUS trial produced a dramatically deeper response: MRD negativity rates increased from 47.5% to 75.2%, and 48-month PFS improved from 67% to 84%.

For transplant-ineligible patients, the MAIA trial (daratumumab + Rd) established Dara-Rd as the standard, while the IMROZ trial demonstrated similar benefit for isatuximab-VRd — giving oncologists two anti-CD38 quadruplet options for TI-NDMM. The net result: anti-CD38 monoclonal antibodies are now embedded in virtually every standard NDMM regimen, and the question for future trial design is no longer "should we add an anti-CD38?" but "what do we add after anti-CD38?"

Transplant eligibility: the organizing principle of NDMM therapy

NDMM trial design and treatment strategy bifurcates around autologous stem cell transplant (ASCT) eligibility. Transplant-eligible (TE) patients — typically those under 70–75 years with good organ function and performance status — receive more intensive induction regimens, mobilization chemotherapy, ASCT, consolidation, and long-term maintenance. Transplant-ineligible (TI) patients receive continuous therapy without ASCT.

Transplant-eligible NDMM: Dara-VRd and the MRD-guided frontier

For TE-NDMM, the current standard is Dara-VRd induction (4–6 cycles), followed by ASCT, then Dara-R maintenance until progression. The AURIGA trial (NCT04898556) tests a refinement: among patients who remain MRD-positive after ASCT, does adding subcutaneous daratumumab to standard maintenance lenalidomide convert them to MRD-negative and improve outcomes? This addresses the 20–25% of TE-NDMM patients who don't achieve MRD negativity even with Dara-VRd + ASCT — a population with significantly inferior prognosis.

A broader question in the field is whether ASCT itself can be omitted for patients who achieve deep MRD negativity after Dara-VRd induction. Multiple trials are evaluating MRD-guided adaptive approaches where transplant is reserved for patients who don't achieve MRD negativity after effective induction. This would represent a major paradigm shift from a procedure-driven to a response-driven ASCT decision.

Transplant-ineligible NDMM: quadruplets and continuous therapy

For TI-NDMM, both Dara-Rd (MAIA) and Isa-VRd (IMROZ) are Phase 3-validated options. IMROZ added bortezomib to the isatuximab backbone, producing MRD negativity rates of 55.5% versus 25.7% for VRd alone and PFS HR of 0.60. The differences between Dara-based and Isa-based regimens are primarily in administration schedules, the exact component combination, and subtle differences in tolerability — not clearly in efficacy, leaving the choice largely based on institutional preference and patient factors.

Bispecific antibodies entering the front-line: consolidation and maintenance trials

The success of BCMA-directed bispecific antibodies (teclistamab, elranatamab) in RRMM has prompted their early-line investigation. The rationale is compelling: bispecifics produce high rates of deep MRD-negative responses even in heavily pretreated RRMM. Moving them earlier — to consolidation after ASCT or as maintenance — might deepen responses achieved with Dara-VRd induction and produce sustained MRD negativity in patients who remain MRD-positive after standard treatment.

The NDMM bispecific strategy does introduce complexity. Bispecifics require step-up dosing to manage cytokine release syndrome (CRS) risk, and their optimal duration of therapy in a consolidation/maintenance setting is unknown. Infection risk from bispecific-induced hypogammaglobulinemia is a significant concern in a setting where patients are already immunocompromised from prior myeloma therapy. Phase 2 data from teclistamab and elranatamab consolidation cohorts are emerging in 2025–2026 and will inform Phase 3 trial design.

CELMoDs: the next-generation IMiD class in front-line development

Cereblon E3 ligase modulators (CELMoDs) — iberdomide and mezigdomide — are the evolutionary successors to lenalidomide and pomalidomide within the immunomodulatory drug class. They bind cereblon with higher affinity and produce deeper degradation of Ikaros and Aiolos transcription factors, generating superior activity in IMiD-resistant cell lines and in patients refractory to lenalidomide and pomalidomide.

The most important question for NDMM: can CELMoDs replace lenalidomide in the Dara-VRd backbone and produce even higher MRD-negativity rates? The SUCCESSOR program (mezigdomide) is testing this hypothesis. If Dara + PI + CELMoD + dex produces deeper responses than Dara-VRd in a Phase 3 setting, CELMoDs could eventually displace lenalidomide in first-line therapy — a massive commercial opportunity given that lenalidomide generates over $6 billion annually in myeloma maintenance alone.

CAR-T in newly diagnosed multiple myeloma: CARTITUDE-5 and early-line ambitions

Ciltacabtagene autoleucel (cilta-cel, Carvykti) is approved for RRMM after at least one prior line of therapy. The CARTITUDE-5 Phase 3 trial (NCT04524936) is testing cilta-cel in transplant-eligible NDMM — comparing it against Dara-VRd + ASCT, the current standard. If CARTITUDE-5 demonstrates superior outcomes versus Dara-VRd + ASCT in TE-NDMM, it would represent one of the most significant shifts in myeloma treatment paradigm in a generation: front-line CAR-T potentially replacing autologous transplant.

The manufacturing challenges of CAR-T remain significant in the NDMM setting. At NDMM, the patient is earlier in their disease course and has not received prior lymphodepleting chemotherapy, potentially changing T-cell fitness and collection efficiency. Manufacturing capacity constraints — which have been the primary limitation on CAR-T access in RRMM — would be even more severe if CAR-T moves to a first-line indication affecting the full NDMM patient population. Scale-up of manufacturing infrastructure is therefore a critical variable in the commercial success of front-line CAR-T.

High-risk cytogenetics: the persistent unmet need

Despite the transformation of NDMM outcomes with daratumumab-based quadruplets, patients with high-risk cytogenetics — particularly deletion 17p (TP53), translocation t(4;14), and translocation t(14;16) — continue to have substantially worse outcomes. These patients often achieve initial MRD-negative responses but relapse faster, suggesting that depth of initial response does not compensate for the aggressive biology driving these tumors.

Multiple dedicated trials for high-risk NDMM are exploring intensification strategies: tandem ASCT (two sequential transplants), adding a fourth or fifth drug to the induction backbone, or using bispecifics early in the consolidation window specifically for high-risk patients. The challenge is that this population is heterogeneous — del(17p) at >50% clone frequency is considered very high risk, while <50% clone frequency confers less-certain risk — and trials have historically been underpowered to make definitive conclusions about the highest-risk subgroups.

Related clinical trials and monitoring resources

Newly diagnosed multiple myeloma is connected to a large adjacent landscape of clinical research. DataLookout monitors related areas including:

• Multiple myeloma clinical trials — full myeloma pipeline across all lines of therapy
• Relapsed/refractory multiple myeloma clinical trials — RRMM is where most trial activity occurs; drugs proven here move earlier to NDMM
• Acute myeloid leukemia clinical trials — hematologic malignancy with overlapping drug classes (venetoclax, HMAs)
• Chronic lymphocytic leukemia clinical trials — CLL shares some investigational agents (bispecifics, BTK inhibitors in related B-cell biology)

Frequently asked questions

What is the current standard of care for newly diagnosed multiple myeloma?

As of 2026, daratumumab-based quadruplet therapy is the global standard. For transplant-eligible patients, Dara-VRd (daratumumab + bortezomib + lenalidomide + dexamethasone) followed by ASCT and Dara-R maintenance is the preferred approach, established by the PERSEUS Phase 3 trial (NCT03652064), which showed 84% 48-month PFS and 75% MRD-negativity rates. For transplant-ineligible patients, Dara-Rd (MAIA trial) and Isa-VRd (IMROZ trial, NCT03319667) are both Phase 3-validated options. The therapeutic standard has moved rapidly and most patients who received VRd alone as recently as 2022–2023 would now be treated differently.

What is the PERSEUS trial and why does it matter?

PERSEUS (NCT03652064) is the Phase 3 trial that established Dara-VRd as the standard for transplant-eligible NDMM. It compared Dara-VRd induction, ASCT, consolidation, and Dara-R maintenance versus VRd + ASCT + R maintenance in transplant-eligible NDMM. Published in NEJM in 2024, PERSEUS demonstrated superior PFS (HR 0.42) and substantially higher MRD-negativity rates (75.2% vs. 47.5%). These results drove regulatory approval of Dara-VRd in the TE-NDMM setting and effectively rendered VRd-only induction obsolete for fit patients with access to daratumumab.

What are the key open questions in NDMM therapy?

Despite the success of Dara-VRd, critical questions drive the current NDMM trial landscape: (1) Can bispecifics or CAR-T improve outcomes as consolidation or maintenance after standard induction? (2) Should ASCT be omitted for MRD-negative patients, or is the transplant still additive? (3) Can CELMoDs (mezigdomide, iberdomide) replace lenalidomide in quadruplets for deeper MRD negativity? (4) For high-risk cytogenetics, does intensified therapy compensate for aggressive biology? The AURIGA, CARTITUDE-5, SUCCESSOR, and bispecific consolidation trials are each addressing one of these questions in active Phase 2/3 programs.

What is high-risk multiple myeloma?

High-risk NDMM is defined by cytogenetic abnormalities — primarily del(17p), t(4;14), and t(14;16) — associated with shorter remissions and inferior survival even with standard quadruplet therapy. Gain or amplification of 1q21 is increasingly recognized as an additional high-risk feature. These patients often achieve initial deep responses but relapse early, and the field lacks consensus on optimal intensification strategies. Current trials are testing tandem ASCT, bispecific antibody consolidation, and CELMoD-based regimens specifically in high-risk NDMM patients.

How can I track new NDMM clinical trials?

DataLookout monitors ClinicalTrials.gov daily and sends filtered email digests for newly diagnosed multiple myeloma. Configure alerts for "newly diagnosed myeloma", "NDMM", "daratumumab induction", "transplant-eligible myeloma", or specific drugs like mezigdomide or cilta-cel. The free plan covers one profile with weekly alerts; Starter ($49/month) provides daily alerts and up to five profiles; Pro ($149/month) offers unlimited profiles. Setup takes under five minutes at datalookout.com.